Evolving approaches with interferon alfa in chronic myelogenous leukemia.
Morra
E
E
Institute of Hematology, University of Pavia, Italy.
Alimena
G
G
Lazzarino
M
M
Liberati
A M
AM
Montefusco
E
E
Bernasconi
P
P
Mancini
M
M
Donti
E
E
Merante
S
S
Caricchi
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D006918:Hydroxyurea